Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
5
100%

Phase Distribution

5

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 15 (100.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completedphase_1

A Study of CDX-0159 in Patients With Prurigo Nodularis

NCT04944862
completedphase_1

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

NCT04538794
completedphase_1

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

NCT04548869
completedphase_1

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

NCT05031624
completedphase_1

A Phase 1 Study of CDX-0159

NCT04146129

Clinical Trials (5)

Showing 5 of 5 trials
NCT04944862Phase 1

A Study of CDX-0159 in Patients With Prurigo Nodularis

Completed
NCT04538794Phase 1

A Study of CDX-0159 in Patients With Chronic Spontaneous Urticaria

Completed
NCT04548869Phase 1

A Single Dose Study of the Safety, Pharmacokinetics and Pharmacodynamics of CDX-0159 in Patients With Cold Contact Urticaria, Symptomatic Dermographism, or Cholinergic Urticaria

Completed
NCT05031624Phase 1

A Phase 1 Study of Subcutaneous CDX-0159 in Healthy Subjects

Completed
NCT04146129Phase 1

A Phase 1 Study of CDX-0159

Completed

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5